Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 9/20 | 0.61 |
| ▸ | KCNQ2 | O43526 | 9/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 8/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 8/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | VNN1 | O95497 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457431 | 1.00 | NPC1 (0.62) | NPC1RXFP1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL7440808 | 0.88 | NAPRT (0.72) | NPC1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2475597 | 0.85 | NAPRT (0.62) | NPC1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL31473447 | 0.83 | NAPRT (0.66) | NPC1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL25981388 | 0.83 | NPC1 (0.59) | NPC1RXFP1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL3383611 | 0.83 | NAPRT (0.66) | NPC1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL16460479 | 0.82 | KCNQ3 (0.62) | NPC1RXFP1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL17676098 | 0.81 | RAB9A (0.64) | NPC1KCNQ3KCNQ2NAPRTDGAT1 | |
| SCHEMBL5305773 | 0.81 | NAPRT (0.58) | NPC1RXFP1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL5046191 | 0.81 | NPC1 (0.66) | NPC1RXFP1KCNQ3KCNQ2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-4736037-A | 2-halo-aryl-pyridinemethanols with analgesic or antiinflammatory activity | LACER, S.A. (ES) | 1988-04-05 | — | — | US | disclosed |
| US-4614833-A | 2-halo-pyridines | LACER, S.A. (ES) | 1986-09-30 | — | — | US | disclosed |
| EP-0032516-B1 | NEW 2-HALO-PYRIDINES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | LACER, S.A. (ES) | 1984-05-02 | — | — | EP | disclosed |
| EP-0032516-A1 | New 2-halo-pyridines, their production and pharmaceutical compositions | LACER, S.A. (ES) | 1981-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 1123/4885RXFP1 49/4885KCNQ3 1333/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 1123/4885RXFP1 49/4885KCNQ3 1333/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | NPC1 510/4885RXFP1 2403/4885KCNQ3 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.